Previous studies have demonstrated that some 30% of COVID-19 in-patients receive antibiotics for community-acquired pneumonia, compared to about 5% with confirmed bacterial infections. Pulia and colleagues sought to assess whether there was a clinical benefit for these patients versus concerns of antibiotic stewardship and individual patient harms.

Their retrospective cohort study using a healthcare database found no significant difference in outcomes for those patients who received antibiotics for community acquired pneumonia on day one as well as other interventions.

Read the article here.